Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial | Zendy

Sebastian Bauer | Zendy; Robin L. Jones | Zendy; JeanYves Blay | Zendy; Hans Gelderblom | Zendy; Suzanne George | Zendy; Patrick Schöffski | Zendy; Margaret von Mehren | Zendy; John Zalcberg | Zendy; YoonKoo Kang | Zendy; Albiruni Abdul Razak | Zendy; Jonathan C. Trent | Zendy; Steven Attia | Zendy; Axel Le Cesne | Zendy; Ying Su | Zendy; Julie Meade | Zendy; Tao Wang | Zendy; Matthew L. Sherman | Zendy; Rodrigo RuizSoto | Zendy; Michael C. Heinrich | Zendy

Open Access

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Author(s) -

Sebastian Bauer,

Robin L. Jones,

JeanYves Blay,

Hans Gelderblom,

Suzanne George,

Patrick Schöffski,

Margaret von Mehren,

John Zalcberg,

YoonKoo Kang,

Albiruni Abdul Razak,

Jonathan C. Trent,

Steven Attia,

Axel Le Cesne,

Ying Su,

Julie Meade,

Tao Wang,

Matthew L. Sherman,

Rodrigo RuizSoto,

Michael C. Heinrich

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.22.00294

Subject(s) - medicine , sunitinib , gist , hazard ratio , imatinib , clinical endpoint , gastroenterology , tyrosine kinase inhibitor , imatinib mesylate , oncology , progression free survival , surgery , randomized controlled trial , confidence interval , cancer , stromal cell , chemotherapy , myeloid leukemia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research